SCHOTT Pharma AG & Co. KGaA

Research SCHOTT Pharma AG & Co. KGaA (1SXP) on Bullrun: market cap EUR 3.31B, P/E 24.4, dividend yield 0.8%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is EUR 3.31B; P/E is 24.4; dividend yield is 0.8%.

Peer valuation comparison

Latest P/E is 24.39x versus a Healthcare sector median of 24.46x.

Latest dividend yield is 0.77% versus a Healthcare sector median of 2.11% (63.5% below).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025EUR 996.56MEUR 150.74MEUR 11.18M33.7%n/aEUR 24.59MEUR 83.01MEUR 930.17M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-15EUR 3.31B24.40.8%0.18

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0.18 EUR, yield 0.8%.

About SCHOTT Pharma AG & Co. KGaA

SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide. The company offers syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a polymer syringe; SCHOTT TOPPAC cosmetic, a polymer syringe for aesthetic treatments;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is SCHOTT Pharma AG & Co. KGaA's market cap?

SCHOTT Pharma AG & Co. KGaA's market capitalization is EUR 3.31B.

What is SCHOTT Pharma AG & Co. KGaA's P/E ratio?

SCHOTT Pharma AG & Co. KGaA's price-to-earnings (P/E) ratio is 24.4.

Does SCHOTT Pharma AG & Co. KGaA pay a dividend?

SCHOTT Pharma AG & Co. KGaA has a dividend yield of 0.8%.

What does SCHOTT Pharma AG & Co. KGaA do?

SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide.